Immunovant, INC Form 4 insider transactions

Atul Pande, a Director of Immunovant, Inc., sold 1,500 shares of common stock on July 24, 2026 for $39.80 per share.

Tiago Girao, Chief Financial Officer of Immunovant, Inc., sold 6,798 shares of common stock on July 23, 2026 for $38.69 per share.

Jay S Stout, Chief Technology Officer of Immunovant, Inc., sold 2,857 shares of common stock on July 23, 2026 for $38.69 per share.

Immunovant's Chief Operating Officer, Melanie Gloria, sold company shares to cover tax obligations related to restricted stock unit vesting.

Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold shares to cover tax obligations related to RSU vesting, a non-discretionary transaction.

Immunovant's Chief Technology Officer, Jay Stout, sold company shares to cover tax obligations related to vesting restricted stock units.

Immunovant CEO Eric Venker settled vested appreciation rights and sold shares to cover tax obligations, as detailed in a Form 4 filing.

Immunovant, Inc. reports that Chief Operating Officer Melanie Gloria sold a total of 17,714 shares of common stock on June 26, 2026.

Immunovant's Chief Technology Officer, Jay Stout, reported the sale of common stock totaling 39,999 shares in multiple transactions on June 26, 2026.

Immunovant, Inc. (IMVT) Chief Legal Officer Christopher Van Tuyl acquired stock options and sold a significant number of common shares on June 26, 2026.

Immunovant's Chief Financial Officer, Tiago Girao, reported a transaction involving the sale of 10,000 shares and the acquisition of 10,000 stock options.

Immunovant, Inc. director Atul Pande reported transactions involving common stock and stock options, executed under a Rule 10b5-1 trading plan.

Immunovant, Inc. director Atul Pande reported transactions involving company stock, including the acquisition of shares under a Rule 10b5-1 plan and the disposal of shares.

Immunovant Chief Operating Officer Melanie Gloria sold 3,115 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Director Atul Pande executed a pre-planned sale of 6,000 shares of Immunovant, Inc. at $32.00 per share following an option exercise.

Director Robert Susman sold 2,502 shares of Immunovant, Inc. common stock via a pre-arranged Rule 10b5-1 trading plan.

Immunovant CFO Tiago Girao sold 25,760 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 5,165 shares of common stock to cover tax obligations related to vested restricted stock units.

Immunovant, Inc. reports that Chief Operating Officer Melanie Gloria sold 8,722 shares of common stock to cover tax withholding obligations upon the vesting of restricted stock units.

Immunovant's Chief Technology Officer, Jay Stout, sold company shares to cover tax obligations related to vesting restricted stock units.

Immunovant, Inc. reports that Director Frank Torti acquired 174,189 shares of common stock and 88,325 stock options.

Immunovant, Inc. Director Andrew J. Fromkin acquired 13,880 shares of common stock and was granted options for 7,061 shares.

Immunovant, Inc. reports a Form 4 filing detailing a Director's acquisition of common stock and stock options.

Director Atul Pande of Immunovant, Inc. reported transactions involving restricted stock units and stock options.

Immunovant, Inc. Director Jake Bauer reported the acquisition of 13,880 shares of common stock and 7,061 stock options on April 7, 2026.

Immunovant, Inc. Director Robert Graham Susman acquired restricted stock units and stock options, reflecting a significant stake in the company's future.

Immunovant, Inc. reports that Chief Operating Officer Melanie Gloria acquired stock options and restricted stock units on April 7, 2026.

Immunovant's Chief Technology Officer, Jay Stout, acquired stock options and restricted stock units (RSUs) on April 7, 2026, as detailed in a Form 4 filing.

Immunovant's Chief Legal Officer, Christopher Van Tuyl, acquired restricted stock units and stock options, indicating insider confidence in the company's future.

Immunovant CEO Eric Venker acquired stock options and restricted stock units, signaling continued commitment to the company's growth.